A comparative trial of clofibrate and nicotinyl alcohol tartrate in hyperlipoproteinemic patients. 1979

C A Dujovne, and D L Azarnoff, and P Pentikainen, and C V Manion, and A Hurwitz

The effects of nicotinyl alcohol tartrate (Roniacol) and clofibrate (Atromid-S) on plasma cholesterol, triglycerides and lipoprotein cholesterol concentrations were compared in 19 patients with hyperlipoproteinemia in a 32-week, double-blind, crossover trial. Determination of serum clofibric acid concentrations, used to check compliance, allowed us to detect an error in the order in which the drugs were dispensed. Both drugs decreased (p less than 0.01) plasma cholesterol approximately 17% in patients with type II hyperlipoproteinemia. Nicotinyl alcohol reduced plasma triglycerides by 20% in six and clofibrate in eight of the nine patients with type IV hyperlipoproteinemia, although the mean effect was not statistically significant due to the large variance. Both drugs decreased (p less than 0.02) very low density lipoprotein (VLDL) cholesterol in the type IV patients; however, clofibrate increased (p less than 0.05) low density lipoprotein (LDL) cholesterol, whereas nicotinyl alcohol did not. Neither drug altered high density lipoprotein (HDL) levels significantly. In future studies, the effect of hypolipidemic drugs on the major classes of plasma lipoproteins should be determined in addition to the response of plasma lipids.

UI MeSH Term Description Entries
D006949 Hyperlipidemias Conditions with excess LIPIDS in the blood. Hyperlipemia,Hyperlipidemia,Lipemia,Lipidemia,Hyperlipemias,Lipemias,Lipidemias
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D008075 Lipoproteins, HDL A class of lipoproteins of small size (4-13 nm) and dense (greater than 1.063 g/ml) particles. HDL lipoproteins, synthesized in the liver without a lipid core, accumulate cholesterol esters from peripheral tissues and transport them to the liver for re-utilization or elimination from the body (the reverse cholesterol transport). Their major protein component is APOLIPOPROTEIN A-I. HDL also shuttle APOLIPOPROTEINS C and APOLIPOPROTEINS E to and from triglyceride-rich lipoproteins during their catabolism. HDL plasma level has been inversely correlated with the risk of cardiovascular diseases. High Density Lipoprotein,High-Density Lipoprotein,High-Density Lipoproteins,alpha-Lipoprotein,alpha-Lipoproteins,Heavy Lipoproteins,alpha-1 Lipoprotein,Density Lipoprotein, High,HDL Lipoproteins,High Density Lipoproteins,Lipoprotein, High Density,Lipoprotein, High-Density,Lipoproteins, Heavy,Lipoproteins, High-Density,alpha Lipoprotein,alpha Lipoproteins
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009540 Nicotinyl Alcohol Alcohol analog of NICOTINIC ACID which is a direct-acting peripheral vasodilator that causes flushing and may decrease blood pressure. It is used in vasospasm and threatened GANGRENE. Nicotinic Alcohol,Nicotinyltartrate,Pyridylcarbinol,3-Hydroxymethylpyridine,Nicomethanol Hydrofluoride,Pyridine-3-Methanol,Radecol,Roniacol,Ronicol,Ronicol Retard,beta-Pyridylcarbinol,3 Hydroxymethylpyridine,Alcohol, Nicotinic,Alcohol, Nicotinyl,Hydrofluoride, Nicomethanol,Pyridine 3 Methanol,beta Pyridylcarbinol
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D002994 Clofibrate A fibric acid derivative used in the treatment of HYPERLIPOPROTEINEMIA TYPE III and severe HYPERTRIGLYCERIDEMIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986) Athromidin,Atromid,Atromid S,Clofibric Acid, Ethyl Ester,Ethyl Chlorophenoxyisobutyrate,Miscleron,Miskleron,Chlorophenoxyisobutyrate, Ethyl

Related Publications

C A Dujovne, and D L Azarnoff, and P Pentikainen, and C V Manion, and A Hurwitz
January 1957, British medical journal,
C A Dujovne, and D L Azarnoff, and P Pentikainen, and C V Manion, and A Hurwitz
February 1975, Angiology,
C A Dujovne, and D L Azarnoff, and P Pentikainen, and C V Manion, and A Hurwitz
December 1963, JAMA,
C A Dujovne, and D L Azarnoff, and P Pentikainen, and C V Manion, and A Hurwitz
January 1980, Artery,
C A Dujovne, and D L Azarnoff, and P Pentikainen, and C V Manion, and A Hurwitz
January 1968, Journal of atherosclerosis research,
C A Dujovne, and D L Azarnoff, and P Pentikainen, and C V Manion, and A Hurwitz
May 1969, Nordisk medicin,
C A Dujovne, and D L Azarnoff, and P Pentikainen, and C V Manion, and A Hurwitz
January 1976, Proceedings of the Royal Society of Medicine,
C A Dujovne, and D L Azarnoff, and P Pentikainen, and C V Manion, and A Hurwitz
January 1975, Atherosclerosis,
C A Dujovne, and D L Azarnoff, and P Pentikainen, and C V Manion, and A Hurwitz
October 1965, La Clinica terapeutica,
C A Dujovne, and D L Azarnoff, and P Pentikainen, and C V Manion, and A Hurwitz
April 1972, British medical journal,
Copied contents to your clipboard!